Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Jun 2021| BIO126D| BCC Publishing
Report Overview

Report Highlights

The global market for clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a compound annual growth rate (CAGR) of 31.4% for the period of 2020-2025.

Report Includes

  • 29 data tables and 73 additional tables
  • An updated review of the global market for emerging clinical applications of the next-generation sequencing (NGS) based diagnostics and related technologies
  • Analyses of the global market trends, with data from 2019-2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenario, and penetration of NGS-based diagnostics and technologies within the industry
  • Estimation of the current market size and revenue forecasts for the global NGS diagnostic markets, and corresponding market share analysis by disease indication, test complexity, test purpose, application and geographic region
  • Evaluation of the key NGS workflow portions of the industry (e.g., sequencing instruments, pre-sequencing target preparation and capture, and post-sequencing data analysis) and the main clinical indications where NGS will capture significant market share by 2025
  • Assessment of main sequencing technologies and explanation of the importance of genetic variation in clinical testing as well as some of the significant research initiatives affecting clinical NGS applications
  • A summary of the major acquisitions and strategic alliances in the clinical NGS industry from January 2019 through April 2021, including key alliance trends
  • Patent review and significant allotments of the U.S. patents in the liquid biopsy industry
  • Company profiles of the major market players, including Agilent Technologies Inc., Becton, Dickinson and Co. (BD), Koninklijke Philips N.V., Merck KGaA, Novogene Co. Ltd., Oxford Nanopore Technologies Ltd., Qiagen NV, Roche Holding AG,  and Thermo Fisher Scientific Inc.

Report Scope

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2019, 2020 and 2025.

This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.

The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.

The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health and transplant medicine.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the rest of the world.

Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct to consumer testing; and noninvasive prenatal testing.

More than 200 companies in the clinical NGS industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2019 through April 2021, including key alliance trends.

Analyst Credentials

John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.

Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Next-generation Sequencing: Emerging Clinical Applications and Global Markets417 $5,500 Free
Chapter- 1: Introduction8Free DownloadFree
Chapter- 2: Summary and Highlights3$250Free
Chapter- 3: Overview8$106Free
Chapter- 4: Technology Background30$396Free
Chapter- 5: Clinical NGS Initiatives20$264Free
Chapter- 6: Clinical NGS Applications16$211Free
Chapter- 7: Clinical NGS Industry48$633Free
Chapter- 8: Acquisitions and Strategic Alliances30$396Free
Chapter- 9: Clinical NGS Markets100$1,319Free
Chapter- 10: Patent Review8$106Free
Chapter- 11: Company Profiles146$1,926Free
Published - Jun-2017| Analyst - John Bergin| Code - BIO126C

Report Highlights

The global clinical next-generation sequencing (NGS) market reached $2.7 billion in 2016. This market is expected to grow at a compound annual growth rate (CAGR) of 27%, from nearly $3.2 billion in 2017 to $10.5 billion by 2022.

Report Includes

  • An overview of the global market for next-generation sequencing and its emerging clinical applications.
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Examination of the sequencing industry structure for key market segments.
  • Discussion covering the strategies employed by the main companies in the market.
  • Comprehensive company profiles of major players in the field.
Published - Jun-2015| Analyst - John Bergin| Code - BIO126B

Report Highlights

The global clinical next-generation sequencing (NGS) market was valued at $886.1 million in 2014. This market is expected to grow at a compound annual growth rate (CAGR) of 31.3%, from $997.1 million in 2015 to nearly $3.9 billion by 2020.

Report Includes

  • An overview of the global market for next-generation sequencing and its emerging clinical applications.
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
  • Examination of the sequencing industry structure for key market segments.
  • Discussion covering the strategies employed by the main companies in the market.
  • Comprehensive company profiles of major players in the field.
Published - Jul-2013| Analyst - John Bergin| Code - BIO126A

Report Highlights

The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 million in 2013 and $7.6 billion in 2018 for a compound annual growth rate (CAGR) of 71.6%.

Report Includes

  • An overview of the global market for next-generation sequencing and its emerging clinical applications
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • Examination of the sequencing industry structure for the key market segments, as well as strategic alliances and acquisitions, as well as evaluations of sequencing patents
  • Discussion of the strategies of the main companies in the market
  • Comprehensive company profiles of major players in the field
Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Single User License: $5500

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS